Publication | Open Access
Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study
11
Citations
0
References
2017
Year
OncologyPathologyBronchial NeoplasmVs CrizotinibAlex StudyCancer TreatmentMedicineRadiation OncologyLung Cancer
No additional data available for this publication yet. Check back later!